This approach achieved intratumoral dual-gene knockout rates of 58.6% (PLK1) and 52.7% (VEGF), inducing tumor apoptosis and anti-angiogenic effects while synergizing immune checkpoint blockade with gene editing—a paradigm shift in glioblastoma treatment [151]. This evidence concerns the gene VEGFA and neoplasm.